Effects of high dose intravenous pamidronate on disease activity and bone metabolism in patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial [3]

Journal of Rheumatology

Volumn 30, Issue 9, 2003, Pages 2080-2082

  Lodder, Mariette C ^a   Van Pelt, Philomine A ^a   Lems, Willem F ^a   Kostense, Piet J ^a   Koks, Cees H W ^b   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID; PLACEBO;

ADULT; AGED; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LETTER; MALE; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BONE AND BONES; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0041692669     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Van Offel JF, Schuerwegh AJ, Bridts CH, Bracke PG, Stevens WJ, De Clerck LS. Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol 2001;19:13-20.
2. Valleala H, Laitinen K, Pylkkanen L, Konttinen YT, Friman C. Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis - a double blind placebo controlled study. Inflamm Res 2001;50:598-601.
3. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48:396-9.
4. Eggelmeijer F, Papapoulos SE, Van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21:2016-20.
5. Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez LA. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 1994;23:211-4.
6. Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999;26:2318-23.
7. Richards PJ, Williams BD, Williams AS. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology Oxford 2001;40:978-87.
8. Ceponis A, Waris E, Monkkonen J, et al. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis Rheum 2001;44:1908-16.
9. Konttinen YT, Salo T, Hanemaaijer R, et al. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 1999;18:401-12.
10. Valleala H, Friman C, Konttinen Y, Solovieva S, Teronen O, Sorsa T. Inhibition of collagenase by a bisphosphonate-group drug in patients with rheumatoid arthritis. J Rheumatol 2000;27:1570-2.